Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

/cms/10.1021/acs.chemrestox.5b00524/as

Trastuzumab or lapatinib with standard chemotherapy for HER2

Beyond trastuzumab: novel therapeutic strategies in HER2-positive

Final predictive factors for diarrhea and rash derived from the

Pyrotinib-based therapeutic approaches for HER2-positive breast

Frontiers Mechanism of Lethal Skin Toxicities Induced by

Update on systemic treatment for newly diagnosed inflammatory

Interdisciplinary management of EGFR-inhibitor-induced skin

Clinical management of cutaneous adverse events in patients on

Wendy A. Woodward, M.D., Ph.D., Radiation Oncologist

Early Adverse Events predict Survival Outcomes in HER2-positive

/cms/asset/c35530e7-c7ac

Targeted therapeutic options and future perspectives for HER2